Researchers identify new approach to help control drug resistance in leukemia

Mar 24, 2008

Researchers then took this success a step further. Using a method developed in their laboratory to rapidly and accurately forecast drug-resistant Bcr-Abl mutations, Deininger and colleagues established a resistance ‘profile’ for SGX393. Though SGX393 showed a handful of mutation weak spots, the T315I mutation was absent among thousands of samples surveyed in the laboratory. In contrast, T315I was frequently recovered when running the screen with any of the other drugs.

“Because the resistance profile of SGX393 nicely complemented those of the other drugs and none of the drugs individually controlled all of the mutations, we extended our study to look at using a combination of the drugs. Remarkably, we found that the combination of SGX393 with either Sprycel or Tasigna completely suppressed resistance,” said Christopher Eide, research technician. He is a co-author with fellow OHSU Cancer Institute researchers Thomas O’Hare, Ph.D., Jeffrey Tyner, Ph.D., Amie Corbin, and Matthew Wong.

“Our pre-clinical study suggests that rationally combining two Bcr-Abl inhibitors with different resistance profiles could provide a dragnet to protect against resistance,” O’Hare said. “The idea is that each drug is especially adept at handling certain Bcr-Abl mutants and that the drugs can team up to eliminate cells carrying mutants that neither drug could eliminate on its own.”

“The effectiveness and safety of Gleevec for most patients remains remarkable,” said Deininger. “However, it is important for patients to know that, with the addition of a drug such as SGX393 to the set of current approved CML drugs, we may have the therapeutic tools to achieve and maintain even more effective and longer control of their cancer. This is not equivalent to a cure, but it could potentially represent an important advance in the management of CML.”

Source: Oregon Health & Science University

Explore further: Depressive symptoms and pain may affect health outcomes in dialysis patients

add to favorites email to friend print save as pdf

Related Stories

Physicists discuss quantum pigeonhole principle

5 hours ago

The pigeonhole principle: "If you put three pigeons in two pigeonholes at least two of the pigeons end up in the same hole." So where's the argument? Physicists say there is an important argument. While the ...

Giant crater in Russia's far north sparks mystery

7 hours ago

A vast crater discovered in a remote region of Siberia known to locals as "the end of the world" is causing a sensation in Russia, with a group of scientists being sent to investigate.

NASA Mars spacecraft prepare for close comet flyby

7 hours ago

NASA is taking steps to protect its Mars orbiters, while preserving opportunities to gather valuable scientific data, as Comet C/2013 A1 Siding Spring heads toward a close flyby of Mars on Oct. 19.

Giant anteaters kill two hunters in Brazil

7 hours ago

Giant anteaters in Brazil have killed two hunters in separate incidents, raising concerns about the animals' loss of habitat and the growing risk of dangerous encounters with people, researchers said.

Recommended for you

African leaders to launch $100m Ebola emergency battle plan

2 hours ago

The head of the World Health Organization and presidents of the west African countries suffering the world's worst-ever Ebola outbreak were due to meet in Guinea on Friday to launch a $100 million emergency response plan.

Female baby boomers with asthma? You may need help

5 hours ago

Women over the age of 65 face numerous barriers to good health: an increased risk for obesity, greater struggles against poverty and higher rates of asthma with worse health outcomes. An article published in the August issue ...

New guidelines help keep asthma out of 'yellow zone'

5 hours ago

If you have asthma, you may have an asthma action plan with a "stoplight system" to help you recognize and respond to changes and understand when symptoms are getting worse and need more attention. If you're in the green ...

User comments : 0